



Issued by Aldeyra Therapeutics on January 11, 2016

Aldeyra Therapeutics Appoints David J. Clark, M.D. as Chief Medical Officer

Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that David J. Clark, M.D. has joined the Company as its Chief Medical Officer, effective January 11, 2016. Dr. Clark will report directly to Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra.

“Dr. Clark brings significant clinical development experience to the Aldeyra team, with a particular focus on treatments for orphan disease,” commented Dr. Brady. “Furthermore, he has a proven ability to work successfully with the FDA and international regulatory agencies to design and implement both early and late stage trials for a variety of clinical indications across a broad spectrum of therapeutic areas. His knowledge and leadership will be invaluable to the Company as we work to continue to advance potential therapies for aldehyde-related diseases toward the market, and we look forward to his contributions.”

Dr. Clark has 18 years of clinical development experience with big pharma and biotech companies based in the US and EU. Most recently, he served as chief medical officer of Wilson Therapeutics where he led the Company’s Phase 2 program for Wilson Disease and the clinical development planning for its Phase 3 program, including detailed interactions with FDA and EMA. Previously, he held senior medical positions at TransTech Pharma and NormOxys, two biotechnology companies focused on the development of drug candidates in a variety of therapeutic areas, including oncology, cardiovascular and neuroscience. Dr. Clark has also held clinical development roles at Pfizer and SmithKline Beecham. He received his MD from the University of Edinburgh Medical School in Scotland.

About NS2

NS2 is an aldehyde-binding small molecule based on an innovative platform technology focused on trapping aldehydes, which are toxic and pro-inflammatory mediators of numerous diseases. By decreasing aldehyde load, NS2 may mitigate excessive inflammation and address diseases where aldehyde metabolism is impaired, including certain inborn errors of metabolism.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap aldehydes. Aldeyra has initiated clinical testing of NS2 for the treatment of

Sjögren-Larsson Syndrome, noninfectious anterior uveitis, and allergic conjunctivitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com